Pragmatic clinical trial to assess the utility of SLCO1B1, ABCG2, and CYP2C9 preepmtive genotyping and pharmacogenetics training on the incidence of musculoskeletal adverse reactions in patients treated with statins in primary and specialized care. - Ap-PriME

Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa0 个研究点目标入组 1,000 人开始时间: 2024年2月7日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa
入组人数: 1,000

暂无简介。

•Adults, with any type of cardiovascular risk (high, moderate or low): a)In which it is indicated statins as a treatment at any dose. b)Pacients who must be outpatients, recruited in a health care centre (primary attention) or in hospitals (primary or secundary prevention). c)Pacients who must have never taken statins or who have started statin treatment less tan 15 days ago, or who had their statin dose increased or changed to a more potent statin due to bad control of LDL levels in the last 15 days. d)Patients who have to give their inform consent form written

•a)Pacients who statins are not prescribed as standard clinical practice. b)Pacients who suffer a malignant or terminal disease whose live expectancy will be less than 6 months. c)Pacients who have statins contraindicated for treatment d)Pregnant or breast-feeding patients.

发起方